BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 31994022)

  • 1. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
    Richard M; Kaufmann P; Kornberger R; Dingemanse J
    Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam.
    Dingemanse J; Nicolas L; Binkert C
    Fundam Clin Pharmacol; 2013 Dec; 27(6):698-710. PubMed ID: 22849770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.
    Mueller MS; Shakeri-Nejad K; Gutierrez MM; Krause A; Täubel J; Sanderson B; Dingemanse J
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):120-31. PubMed ID: 24126567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
    Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.
    Abadias M; Escriche M; Vaqué A; Sust M; Encina G
    Br J Clin Pharmacol; 2013 Jan; 75(1):103-17. PubMed ID: 22607269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
    Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
    Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
    J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
    Vernillet L; Greene SA; Kamin M
    Clin Pharmacol Drug Dev; 2020 May; 9(4):428-443. PubMed ID: 32087001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.